In vivo studies showed that dendritic cell (DC) dysfunction occurred in tumor microenvironment. As tumors were composed of many kinds of cells, the direct effects of tumor cells on immature DCs (imDCs) are needed for further studies in vitro. In the present study, bone marrow-derived imDCs were incubated with lymphoma, hepatoma and menaloma cells in vitro and surface molecules in imDCs were determined by flow cytometry. Then, imDCs incubated with tumor cells or control imDCs were further pulsed with tumor lysates and then incubated with splenocytes to perform mixed lymphocyte reaction. The DC-dependent tumor antigen-specific T cell proliferation, and IL-12 secretion were determined by flow cytometry, and enzyme-linked immunosorbent assay respectively. 
Introduction
It is well established that tumor cells express many kinds of antigens which could be recognized by dendritic cells (DCs), subsequently activating the tumor-specific T-cell response (1) . However, this response in fact does not usually occur in most types of human cancer or in animal models, indicating that the dysfunction of host immune system including DCs might be one of the main mechanisms by which tumors escape from host immune control (2-6), as well as an important issue to limit the success of cancer immunotherapy (7) . In fact, suppressed DC functions have been reported in various models simulating the tumor microenvironment, and in tumor-bearing animals, as well as in cancer patients (8) (9) (10) . Recently, an in vitro incubation system including irradiated tumor cells, DCs, CD4 + CD25 -T cells was also reported to induce the expansion of human T regulatory type 1 cells (11) . All these co-incubation systems include relative tumor supernatants, soluble tumor-derived factors, irradiated tumor cells, using 0.4 μm diameter pore membrane to observe the soluble factor effect on DC function. But, until now, little is known about the effects of tumor cells on immature DCs (imDCs) by direct tumor cell-imDC contact. Therefore, in vitro studies are urgently needed to explore the effects of live tumor cells on imDCs based on direct tumor cell-DC co-incubation. In the present study, using 8.0-12 μm diameter pore co-incubation system, which permits tumor cells to directly contact on DCs, we co-incubated imDCs with different original tumor cells to study the effect of live tumor cells contact on imDCs. We firstly demonstrated that tumor cell-imDC co-incubation down-regulated surface molecules on imDCs. Secondly, we illustrated that the abilities of DCs in T cell priming and IL-12 secretion were also decreased by such tumor cell-imDC co-incubation. Finally and most importantly, we revealed that the ability of DCs to prime tumor antigenic-specific CTL was obviously decreased by such in vitro co-incubation. Our study indicated that myeloid DC function defects do occur in tumor cell-DC co-incubation system, which might be valuable for studying the tumor-Animals Pathogen-free C57BL/6 mice (female, 6-8 weeks old) were bought from Shanghai Laboratory Animal Center of Chinese Academy of Sciences (China) and kept at the Animal Center of Cancer Institute, Shanghai Jiao Tong University. All animal studies were approved by the Review Board, Cancer Institute, Shanghai Jiao Tong University.
Cell lines
EG7 cell line which carries a complete copy of chicken ovalbumin (OVA) mRNA and the neomycin (G418) resistance gene, was derived from the C57BL/6 (H-2 b ) mouse lymphoma cell line EL4 (ATCC TIB-39) (12) . EG7 cells were cultured in RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.05 mM 2-mercaptoethanol and 0.4 mg/ml G418, 10% FBS (Invitrogen Life Technologies). Hepa 1-6 cell line was a derivative of the BW7756 mouse hepatoma that arose in a C57BL/6 mouse (ATCC CRL-1830) (13) . B16 cell line was derived from C57BL/6 mouse skin melanoma (ATCC CRL-6475) (14) . Hepa 1-6 and B16 cells were cultured in Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, 10% FBS. EG7 and Hepa 1-6 cell lines were obtained from Dr. Cao XT (Second Military Medical University, China). B16 cell line was a kindly gift of Dr. Yao M (Shanghai Jiao Tong University, China).
Preparation of tumor cell lysate
Tumor cell lysate was prepared as previously described (15) . Briefly, Hepa 1-6 and B16 cells cultured in Dulbecco's modified Eagle's medium were harvested using trypsin buffer. EG7 cells, which were cultured in CM, were harvested directly. After two washes with cold PBS, the cell pellet was then resuspended in lysis buffer (20 mM HEPES buffer, 50 mM NaCl, 10 mM KCl, 1 mM EDTA, 200 mM sucrose, pH 7. 4) at a concentration of 2 × 10 6 cells/250 μl.
Tumor cells were then subjected to repeat (6×) freezing at -80°C and thawing at 37°C. After the last thaw, cells were sonicated for 10 s/ml of lysate and centrifuged at 14,000 rpm for 20 min at 4°C. Supernatant was then collected into vials and stored at -80°C.
Bone marrow-derived murine DCs
Bone marrow-derived imDCs were prepared as previously described (16) . Briefly, bone marrow mononuclear cells were prepared from bone marrow suspensions by depletion of red cells and then were cultured at a density of 1 × 10 6 cells/ml in RPMI 1640 complete medium with 10 ng/ml of GM-CSF and 1 ng/ml of IL-4. Non-adherent cells were gently washed out on day 4 of culture; the remaining loosely adherent clusters were used as imDCs which were further coincubated with tumor cells.
DCs co-incubation with tumor cells
To observe the effects of co-incubation with tumor cells on imDCs surface molecules expression and the abilities of DC-dependent antigenic-specific CTL priming, Transwell™ 8.0-12 μm diameter polycarbonate membranes were used to incubate cells according to the methods previously described (17) . Briefly, Transwell™ polycarbonate membranes were wet with media in a 6-well plate, turned upside down, 1 × 10 5 EG7, Hepa 1-6 or B16 cells were added to the outside membrane of the Transwell™ in 400 μl volume respectively and incubated in 37°C CO 2 incubator for 4 hours to allow the cell attachment. Then, Transwell™ was gently turned over and 1 × 10 6 imDC cells were seeded to the inside of the Transwell™. Media was put in the plastic well outside the Transwell™ and incubated for another 14 h. Control cultures containing 1 × 10 6 imDCs alone or pulsed with either 1 × 10 5 tumor cell lysate or ovalbumin 1 μg/ml were used as negative and positive controls. At the end of incubation, DCs were harvested and stained for flow cytometric measurement or pulsed with same amount tumor lysate and performed mixed lymphocyte reactions (MLRs).
Flow cytometric measurement
Expression of cell surface molecules was determined by flow cytometry according to the methods described previously (16) . Before staining with relevant Abs, DCs were incubated for 15 min at 4°C with antibody to CD16/CD32 at a concentration of 1 μg per 1 × 10 6 cells for blockade of Fc receptors. Staining was performed on ice for 30 min and then cells were washed with ice-cold PBS, containing 0.1% NaN 3 and 0.5% BSA. Analysis was performed using FACSCalibur and the mean fluorescene intensity (MFI) of each DCs population was analyzed with CellQuest software.
Antigen-specific T cell proliferation assays
Antigen-specific T cell proliferation assay was performed as described previously (17) and determined by BD Trucount system (16) . Briefly, 1 × 10 6 imDCs were co-incubated with 1 × 10 5 live EG7 or Hepa 1-6 cells for 14 hours in the Transwell™ system. DCs without any treatment or pulsed with either same amount of tumor lysate or OVA 1 μg/ml were used as negative and positive controls. At the end of incubation, imDCs were harvested using trypsin buffer and then pulsed with 1 × 10 5 tumor lysate for another 4 hours. Then, DCs were added to plates containing 1 × 10 5 syngeneic splenocytes at a ratio of 1:10 to perform the MLRs. After 5-7 days incubation, supernatants of MLRs were collected for IL-12 determination by enzyme-linked immunosorbent assays (ELISA) and cells in MLRs were stained with antibodies in exactly 100 μl PBS. Thirty μl stained cells and 470 μl PBS were added to BD Trucount TM tubes and cellular data were acquired for 60 s with a flow cytometry. The number of T cells and control bead events acquired were analyzed, and the number of T cells in each well was calculated according to the formula: Number absolute count = (Number of events in region containing cell / Number of events in absolute count bead region) × (Number of beads per test / test volume).
IL-12 ELISA assay
To determine IL-12 in the supernatants of MLRs, ELISA was performed according to the methods described previously (18) .
Tumor antigen-specific ELISPOT assay
Tumor antigen-specific enzyme-linked immunospot assay (ELISPOT) was performed using published method (19) . Briefly, plate was coated with anti-IFNγ antibody and cells of MLRs were harvested and immediately plated in wells of ELISPOT plates with 1 × 10 5 cells/well. Cells were stimulated with either lymphoma EG7 specific SIINFELK peptide at a final concentration of 1 μg/ml or 1 × 10 5 /ml Hepa 1-6 cells lysate and incubated at 37°C for 16-20 hours. Then, after detective antibody was added, the substrate was added and the spots were counted.
Statistical analysis
All data were expressed as mean and standard error means. Statistical significance was tested using Student's t test. Statistical differences were considered to be significant if p < 0.05.
Results

Co-incubation with TSA cells down-regulates surface molecules on imDCs
Co-stimulatory molecules on DCs are important for immunologic synapse formation, T cell activation and proliferation (1). EG7 cell line, which carries OVA mRNA and the neomycin (G418) resistance gene, is considered as tumor specific antigen (TSA) cell model (12) . To explore the effects of tumor cell co-incubation on imDCs, imDCs were co-incubated with lymphoma EG7 cells in Transwell™ system and surface molecules on imDCs were determined by flow cytometry. As shown in Figure 1 , the expression of surface molecules CD80, and CD86 had less been affected by lymphoma cells co-incubation ( Figures 1A and 1B) . But EG7 cells-DCs co-incubation significantly down-regulated CD40, CD54, CD11a, CD11b and MHC class II molecules on imDCs. In contrast with untreated DCs, the MFI of CD86, CD40, CD54, CD11a, CD11b and MHC class II molecules were decreased by 85%, 78.5%, 89%, 72.6%, 80.7% and 99.3%, respectively ( Figure 1B ). As compared with OVA pulsed DCs control, EG7 cells incubation decreased the MFI of CD40, CD54, CD11a, CD11b and MHC class II molecules to 64.2%, 83.2%, 73%, 70% and 82.8%, respectively ( Figure  1B ).
Co-incubation with TAA cells down-regulates surface molecules on imDCs
As hepatoma Hepa 1-6 and melanoma B16 cells do not express TSA, we further incubated imDCs with either hepatoma or melanoma cells to explore the effects of surface molecule down-regulation on imDCs by such co-incubation. As shown in Figure 2 , co-incubation with either hepatoma or melanoma cells decreased a panel molecules expression except for CD86 and CD40. On the contrary with untreated DCs control, the MFIs of CD80, CD86, CD40, CD54, CD11a, and CD11b were changed to 73.6%, 135.1%, 174.7%, 81.2%, 67% and 89.5% respectively by hepatoma coincubation ( Figure 2B ). As compared with hepatoma lysatepulsed DCs, the MFIs of CD80, CD54 and CD11a were down-regulated to 59.1%, 60.1% and 49.1% respectively by such hepatoma co-incubation ( Figure 2B) considering the results derived from lymphoma EG7 co-incubation expriment, hepatoma Hepa1-6 treatment up-regulated CD86 with MFI increment to 151.5% ( Figure  2B ). Melanoma B16 co-incubation also gave the similar results. Compared to melanoma lysate-pulsed DCs, the MFI of CD11b in DCs was decreased to 66.5% while the MFIs of CD86 and CD40 were up-regulated to about 157.8% and 270.7%, respectively ( Figures 2C and 2D ).
Co-incubation with tumor cells decreased DC ability to stimulate T cell proliferation
DCs are the most efficient antigen presenting cells (APCs), capable of priming naïve T lymphocytes (20) . To further determine tumor cell co-incubation effect on DCs for T cell priming, imDCs co-incubated with either lymphoma or hepatoma cells were pulsed with relative tumor lysate and further incubated with splenocytes for MLRs. As shown in Figure 3 , tumor cell co-incubation decreased DC ability for T cell priming. For instance, DCs co-incubated with EG7 cells could only achieve 400 proliferated cells, while EG7 lysate or OVA pulsed DCs could have about 1807 and 1462 cells, respectively, indicating that tumor cells co-incubation decreased DCs ability for T cell priming ( Figure 3A) . Meanwhile, a remarkable decrement on DCs-dependent T cell priming ability was observed by hepatoma co-incubation, as hepatoma lysate-pulsed DCs could get 1365 proliferated cells, compared with 70 cells induced by Hepa 1-6 coincubated DCs.
Tumor cell co-incubation decreased DC ability to produce IL-12
DCs play a crucial role in generation of tumor antigenspecific immune response (21) . As IL-12 is one of the key mediators to promote Th1 T cell priming (22) , IL-12 in supernatants of MLRs was determined to indicate the ability of DCs-dependent Th1 priming. As shown in Figure 4 secretion in MLRs was seriously impaired by tumor cells co-incubation. For example, EG7 cell pre-incubated imDCs could only produce 51 pg/ml IL-12 in the supernatants of MLRs, while EG7 lysate or OVA pulsed imDCs could produce 925 pg/ml and 3397 pg/ml, respectively ( Figure 4A ). In case of Hepa 1-6 co-incubated imDCs, the similar reduction of IL-12 can be observed ( Figure 4B ). We noticed that the controls in two independent experiments have different IL-12 levels. This might be due to the difference in MLRs performance, animal age or ELISA procedures.
Co-incubation with tumor cells decreases CTL priming ability of DCs in vitro
As tumor co-incubation decreased the DCs' ability of T cell priming, additional experiments were needed to further explore if such co-incubation could impair the ability of antigenic-specific CTL priming which is essential for antitumor immunity. To this end, IFN-γ + tumor antigenspecific CTL in MLRs was determined with ELISPOT assays in the presence of either EG7 specific SIINFELK peptide or hepatoma lysate. As shown in Figure 5 , tumor cell co-incubation could substantially reduce DC ability to prime antigen-specific CTL. EG7 incubated DCs could only develop 59 spots in contrast to 123 and 221 spots of EG7 lysate or OVA pulsed DCs respectively ( Figure 5A ). The dysfunction of lymphoma incubated DCs for CTL priming was also confirmed in hepatoma incubation DCs with 3 and 95 spots in hepatoma incubated or hepatoma lysate pulsed DCs respectively ( Figure 5B ).
Discussion
It is well known that many tumors are potentially immunogenic (1) . DCs are specialized APCs that recognize, acquire, process and present antigens to naïve T cells for the induction of an antigen-specific immune response (1). However, the presence of functional immunogenic mature DCs is rare in both human tumors, such as ovarian (3), breast tumors (4), prostate cancer (5) and in renal-cell carcinomas (6) . In the present study, bone marrow-derived, GM-CSF and IL-4 induced myeloid imDCs were incubated in 8.0-12 μm Transwell TM system with lymphoma, hepatoma, and melanoma cells in vitro to directly observe the effects of co-incubated imDCs in surface molecule expression, IL-12 secretion, DCs-dependent T cell proliferation and tumor antigen-specific CTL priming. Our results showed that co-incubation with either TSA-lymphoma EG7 cells or TAA hepatoma and melanoma cells, decreased surface molecule expressions of CD54, CD11a, CD11b and MHC class II molecules on imDCs. It is reported that the onset and regulation of a specific immune response were resulted from immunological synapse (23, 24) , which consists of three phases: contact acquisition, formation of an interaction plane and detachment of the T cell (24) . In the first phase, the immunological-synapse formation occurs when moving T cells recognize DCs through peptide-MHC complexes and CD11a, CD11b, CD54, leading to a transient arrest in migration (25) . Meanwhile, the impact of the type and activation status of the APCs on the duration of the cell-cell interaction seems to be correlated with the co-stimulatory capacity and activation potency of the APCs (26) . Although several reports have described inhibitory effects of soluble tumor-derived factors such as IL-6, IL-10, TGF-β, vascular endothelial growth factor, and gangliosides on DCs (27) (28) (29) , the down-regulation of surface molecules on imDCs induced by tumor cell co-incubation might also inhibit the direct interaction between T cell and DCs at the first phase of immunological synapse formation, hence decreasing the DC-dependent T cell activation and proliferation. However, in our experiments, we found some controversial results of a few surface markers on imDCs co-incubated with tumor cells from different origins. For example, CD40 was downregulated (p < 0.05) and CD86 was not altered (p > 0.05) on TSA-lymphoma incubated DCs, but these two molecules were up-regulated on hepatoma and melanoma incubated imDCs. These differences might be attributed to different types of tumor cells used for DCs co-incubation and their relevant antigenicity. Up-regulation of CD40 and CD86 on spleen DCs were also observed in animals after subcutaneous and intraperitoneal administration of lymphoma cells (11) .
For the mechanism of DC-T cell direct interaction, the fate of naïve Th cells is presumably determined by three signals that are provided by pathogen-primed mature DCs (30) . Signal 1 is delivered through the T-cell receptor (TCR) when it engages an appropriate peptide-MHC complex. Signal 2 is referred to the fine balance of positive and negative co-stimulatory signals (30) , which in collaboration with signal 1 induces immunity and is often measured as T cell expansion and differentiation into effector cells (31) . Signal 3 comprises of signals delivered from the APCs to the T cells to commit their differentiation into Th1 cells, Th2 cells or CTLs (32) . In the present study, the down-regulation of surface molecules on DCs was observed by tumor cell co-incubation. These results might suggest that tumor cell-incubated DCs could only generate minor signal 1 and signal 2 related molecules. The non-specific immunological synapse between naïve T cell and DC often generates a weak signal, such as minor tyrosine phosphorylation and calcium influx, which is not potent enough to initiate primary T-cell activation and proliferation (24) . It was not surprising to find that tumor-treated DCs could achieve less DCs-dependent T cell proliferation and antigen-specific CTL priming. As IL-12 is one of the key mediators of signal 3 to promote Th1-cell or CTL development (33) , the decrements of IL-12 secretion and effectors CTL priming in our data might indicate that tumor cells-incubated DCs failed to induce the differentiation of T cells with full function (34) .
As shown in our data, the present tumor cell-DC coincubation does reveal the DC dysfunction attributed to the direct interaction by tumor cells, thereby providing a method capable of dissecting the tumor cell-DC interaction in tumor microenvironment. However, we have to address that the stroma of tumor is much more complex than the present tumor cell and DC two co-culture. In fact, tumor tissues comprise of tumor cells, tumor-associated fibroblasts, vascular endothelial cells, extracellular matrix and different variety of immune cells, including DCs, macrophages, granulocytes and others. There are a complex interaction networks among these cells and elements. Cao's group has demonstrated that regulatory DCs cell are generated after co-incubation with spleen stromal cells, which have inhibitory effect on T cell proliferation (16) . Moreover, a number of molecules, such as cyclooxygenase-2 (COX2), prostaglandin E2 (PGE2), IL-10, IL-6, vascular endothelial growth factor (VEGF), gangliosides and TGF-β, secreted by tumor and tumor-associated macrophages, also suppress DC maturation and function (27) (28) (29) . Therefore, the interaction among cell elements and their secretary molecules needs further extensive studies.
Taken together, our results demonstrated that coincubation with tumor cells could down-regulate the surface molecules on imDCs and decrease the ability of DC to prime T cell proliferation. It was further revealed that the DCdependent antigen-specific CTL priming was also ablated, indicating that tumor-induced myeloid DC defects occurred in the present tumor cell-DC co-incubation condition. This co-culture system provides an experimental model in vitro for studies of immunological dysfunction in cancer, which is valuable for studying the tumor-immune cells direct interaction and for future immune-modulation drug screening.
